BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33599857)

  • 1. A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer.
    Li S; Gao P; Qiu J; He X; Mao Y
    J Thromb Thrombolysis; 2021 Oct; 52(3):898-903. PubMed ID: 33599857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of a Modified Khorana Score for Predicting Venous Thromboembolism in Newly Diagnosed Stage IV Lung Cancer.
    Qin Y; Liang X; Wu H; Sun X; Yan S; Wang N; Yuan M; Wang Q; Wu D
    Angiology; 2023 Nov; ():33197231213197. PubMed ID: 37924222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data.
    Tsubata Y; Kawakado K; Hamai K; Furuya N; Yokoyama T; Saito R; Nakamura A; Masuda T; Hamaguchi M; Kuyama S; Honda R; Senoo T; Nakanishi M; Hotta T; Yamasaki M; Ishikawa N; Fujitaka K; Kubota T; Kobayashi K; Isobe T
    Int J Clin Oncol; 2023 Jan; 28(1):69-78. PubMed ID: 36357710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer.
    Parker A; Peterson E; Lee AYY; de Wit C; Carrier M; Polley G; Tien J; Wu C
    J Thromb Haemost; 2018 Jul; 16(7):1321-1326. PubMed ID: 29733498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of risk factors for venous thromboembolism and evaluation of Khorana venous thromboembolism risk assessment in Japanese lung cancer patients.
    Hiraide M; Shiga T; Minowa Y; Nakano Y; Yoshioka H; Suzuki K; Yasuda C; Takahashi H; Hama T
    J Cardiol; 2020 Jan; 75(1):110-114. PubMed ID: 31416782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.
    Pépin M; Kleinjan A; Hajage D; Büller HR; Di Nisio M; Kamphuisen PW; Salomon L; Veyradier A; Stepanian A; Mahé I
    J Thromb Haemost; 2016 Feb; 14(2):306-15. PubMed ID: 26589836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients.
    Rupa-Matysek J; Lembicz M; Rogowska EK; Gil L; Komarnicki M; Batura-Gabryel H
    Med Oncol; 2018 Apr; 35(5):63. PubMed ID: 29616356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer.
    Shaw JR; Kumar V; Mallick R; Carrier M; Ilich A; Key NS; Wells P
    Thromb Res; 2020 Dec; 196():437-443. PubMed ID: 33065408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score.
    Castellón Rubio VE; Segura PP; Muñoz A; Farré AL; Ruiz LC; Lorente JA
    Thromb Res; 2020 Dec; 196():349-354. PubMed ID: 32977135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.
    Abdel-Razeq H; Sharaf B; Al-Jaghbeer MJ; Abu-Fares H; Bater R; Shaer MA; Abu-Jaish H; Laban DA; Salamah O; Tamimi F; Ashouri K; Salameh T; Zughul R; Alhalaseh Y
    J Thromb Thrombolysis; 2023 Oct; 56(3):447-453. PubMed ID: 37430158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.
    Ramos JD; Casey MF; Bamias A; De Giorgi U; Bellmunt J; Harshman LC; Ladoire S; Wong YN; Alva AS; Rosenberg JE; Galsky MD; Yu EY;
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):755-760. PubMed ID: 27637910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).
    Kuderer NM; Poniewierski MS; Culakova E; Lyman GH; Khorana AA; Pabinger I; Agnelli G; Liebman HA; Vicaut E; Meyer G; Shepherd FA
    Oncologist; 2018 Feb; 23(2):247-255. PubMed ID: 28951500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk prediction of venous thromboembolism in non-small cell lung cancer patients based on COMPASS-CAT risk assessment model].
    Wang YF; Ma F; Liu BL; Yang K; Li JL; Yu L
    Zhonghua Zhong Liu Za Zhi; 2020 Apr; 42(4):340-345. PubMed ID: 32375452
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison among three predictive models for cancer-associated thromboembolism in a hispanic population.
    Ramos-Esquivel A; Marenco-Flores A; Hernández-Romero G; Céspedes-Calvo A; Mora-Hidalgo R
    J Thromb Thrombolysis; 2023 Oct; 56(3):433-438. PubMed ID: 37407771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predicting the Incidence of Venous Thromboembolism Using the Khorana Score: A Literature Review].
    Nishimura A; Ikeda Y
    Yakugaku Zasshi; 2021; 141(4):611-622. PubMed ID: 33790126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer.
    Mansfield AS; Tafur AJ; Wang CE; Kourelis TV; Wysokinska EM; Yang P
    J Thromb Haemost; 2016 Sep; 14(9):1773-8. PubMed ID: 27273134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models.
    El-Sayed HA; Othman M; Azzam H; Bucciol R; Ebrahim MA; El-Agdar MAMA; Tera Y; Sakr DH; Ghoneim HR; Selim TE
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):17771-17780. PubMed ID: 37935936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study.
    Kruger S; Haas M; Burkl C; Goehring P; Kleespies A; Roeder F; Gallmeier E; Ormanns S; Westphalen CB; Heinemann V; Rank A; Boeck S
    Thromb Res; 2017 Sep; 157():9-15. PubMed ID: 28675831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a predictive score for venous thromboembolism in newly diagnosed non-small cell lung cancer.
    Li J; Yi J; Hua L; Su Y; Huo M; Dou F; Zhai Z; Zhu M; Zhang S; Zhang Y
    Thromb Res; 2021 Dec; 208():45-51. PubMed ID: 34695715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.
    Muñoz A; Ay C; Grilz E; López S; Font C; Pachón V; Castellón V; Martínez-Marín V; Salgado M; Martínez E; Calzas J; Ortega L; Rupérez A; Salas E; Pabinger I; Soria JM
    J Clin Oncol; 2023 Jun; 41(16):2911-2925. PubMed ID: 36730884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.